Clinical Trial Update: Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study [Phase 2]

View source ↗

Summary

Phase II open-label, single-arm multicenter study evaluating a combination of selinexor, high-dose methotrexate, and rituximab with radiotherapy for newly diagn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rheumatrex (methotrexate)
• Rituxan (rituximab)
• XPOVIO (selinexor)

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Lymphomas | Phase 2 | Status: RECRUITING